HemaVision -Screen | HV01-Screen

HemaVisionÒ-Screen is a CE-marked in vitro diagnostic test for 28 leukemia causing chromosomal
translocations including more than 145 breakpoints plus associated mRNA splice variants. Furthermore,
it detects new breakpoints and mRNA splice variants for the 28 translocations. HemaVisionÒ-Screen is a
qualitative test intended for use on total RNA samples from human blood or bone marrow for presence
of chromosomal translocations associated with leukemia. Tests should be performed and results should
be analysed by professionals only. The test is intended for use as an adjunct to evaluation of Leukemia in
conjunction with other clinicopathological factors (aid to diagnosis).
It is a fast one day test based on the method described by Pallisgard et al. (Ref 58). The HemaVisionÒScreen test has very high sensitivity (>99%) and specificity (>99%) (Ref 59, 60).
Limit of detection is 10-9 µg of fusion RNA in a sample of 1 µg total RNA when the RNA quality is good.
This test provides a more detailed description of the exon organization of fusion genes originating from
chromosome translocations.
HemaVisionÒ-Screen is a qualitative test using total RNA extracted from human whole blood or bone
marrow cells as starting material in the test. The test uses reverse transcription of RNA to cDNA followed
by multiplex nested polymerase chain reactions (RT-PCR), agarose gel electrophoresis, and
interpretation.
HemaVisionÒ-Screen identifies chromosomes, genes and exons at the breakpoint in fusion genes.
Furthermore, the test identifies mRNA splice variants from fusion genes.
The HemaVisionÒ-Screen kit contains primers for 25 cDNA reactions and 25 (master) nested PCR tests.
The HemaVisionÒ-Screen kit is identical to the BOX 1 of HemaVisionÒ-28N kit (Cat No HV01-28N).
Therefore, positive master reactions from HemaVisionÒ-Screen tests must be characterized further by
split-out reactions from BOX2 of the HemaVisionÒ-28N kit.
The test is for professional use only.